Previous Article | Next Article 
Journal of Clinical Microbiology, December 1998, p. 3619-3623, Vol. 36, No. 12
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Evaluation of PCR for Detection of DNA Specific for
Aspergillus Species in Sera of Patients with Various
Forms of Pulmonary Aspergillosis
Yuriko
Yamakami,*
Atsuro
Hashimoto,
Eiji
Yamagata,
Perparim
Kamberi,
Reiko
Karashima,
Hiroyuki
Nagai, and
Masaru
Nasu
Second Department of Internal Medicine, Oita
Medical University, Oita, Japan
Received 2 March 1998/Returned for modification 24 June
1998/Accepted 5 September 1998
 |
ABSTRACT |
Pulmonary aspergillosis is classified into invasive, saprophytic,
and allergic forms. In this study, we evaluated the usefulness of PCR
for differentiating between different forms of aspergillosis or in
monitoring disease activity during treatment by detecting DNA specific
for Aspergillus species in the serum. Nested PCR was used
to detect Aspergillus DNA in the sera of 30 patients with
various forms of pulmonary aspergillosis. The results were compared
with those of latex agglutination tests for detecting galactomannan
antigen. We also examined the serial changes in the results of nested
PCR during and after treatment of a subgroup of patients with invasive
pulmonary aspergillosis with amphotericin B. The highest proportion of
positive nested PCR results were in patients with invasive
aspergillosis (10 of 12; 83%), while patients with pulmonary
aspergilloma had the lowest frequency of positive tests (1 of 9; 11%).
These results suggested that the sensitivity of the nested PCR depends
on the extent of invasion by Aspergillus species. Serial
assays showed that the results of nested PCR became negative shortly
after commencement of antifungal treatment and that such changes did
not correlate with clinical responsiveness to treatment. Our results
indicate the potential usefulness of nested PCR with serum samples for
the diagnosis of invasive aspergillosis and the detection of a shift in
the status of infection from a noninvasive type to invasive
aspergillosis. However, the results of the nested PCR did not correlate
with the response to antifungal treatment.
 |
INTRODUCTION |
Pulmonary aspergillosis is
classified into three types: invasive, saprophytic, and allergic. The
type of disease caused by Aspergillus species is determined
by the host immune activity and structural abnormalities of the bronchi
and lung (2, 10, 17). Recently, Gefter et al. (8,
9) proposed a new type of semi-invasive pulmonary aspergillosis
as an intermediate form between the invasive and saprophytic types.
Binder et al. (3) later described a similar condition as
chronic necrotizing pulmonary aspergillosis (CNPA). In spite of this
classification, it is often difficult to differentiate among these
disease forms, and intermediate or borderline cases often exist
(1, 15).
In a series of recent studies, we reported the usefulness of nested PCR
for the detection of DNA specific for Aspergillus species in
serum samples and for the diagnosis of invasive pulmonary aspergillosis
(IPA) (11, 22). In the present study, we evaluated the
usefulness of nested PCR for differentiating between different forms of
pulmonary aspergillosis.
 |
MATERIALS AND METHODS |
Patients.
A total of 30 patients with various types of
pulmonary aspergillosis were included in the study. They represented
consecutive patients admitted to the Second Department of Internal
Medicine at Oita Medical University Hospital and its affiliated
hospitals between November 1992 and September 1997. Serum samples were
obtained from these patients at least twice prior to diagnosis and at
different intervals after treatment (mean number of samples per
patient, 4.7; range, 2 to 12 samples). The same samples were analyzed
by both nested PCR and galactomannan antigen assay. In addition, if the
condition of the patient permitted, bronchoalveolar lavage (BAL) was
performed by standard techniques and BAL fluid samples were cultured
for the detection of Aspergillus species.
Disease types.
The presence or absence of underlying
disorders; serial changes in chest X rays, including the preexistence
of pulmonary cavities; and the clinical course were reviewed to
classify pulmonary aspergillosis into the following categories.
(i) Pulmonary aspergilloma.
Patients with pulmonary
aspergilloma showed fungus balls in preexisting pulmonary cavities
caused by destructive pulmonary diseases, such as tuberculosis. All
patients had positive Aspergillus precipitin tests
(10).
(ii) CNPA.
Patients with CNPA showed pulmonary infiltration
with progressive cavity formation irrespective of the presence or
absence of preexisting pulmonary cavities, indicating chronic pulmonary damage over months to years (3).
(iii) IPA.
Patients with IPA had severe underlying
disorders, such as hematologic malignancies or fever resistant to
antibiotics, and had chest X-ray findings consistent with this type of
disease, such as round pneumonia, cavitation, or extensive infiltration (10). Furthermore, this category was divided into the
following subcategories: (a) proven IPA, comprising those patients with microbiologically or histologically proven IPA; and (b) presumptive IPA, comprising the remainder of the patients, for whom a diagnosis of
IPA was suggested by chest radiograph and other clinical manifestations.
(iv) Aspergillus empyema.
Patients with
Aspergillus empyema had a relatively mild infiltration in
the lungs and apparent pleural effusion. Aspergillus cells
were isolated by the culture of pus obtained by thoracocentesis (4).
Clinical cultures and identification of fungal pathogens.
Routine culture for fungi was performed after centrifugation of the BAL
fluid sample or pleural effusion at 1,200 × g for 10 min. The pellet was plated onto Sabouraud glucose agar and was cultured
for 7 days at 30 and 37°C. Aspergillus species were identified by their culture characteristics and the morphologies of
their conidiophores and conidia.
Nested PCR.
PCR was performed in our laboratory as described
previously (11, 22), with two sets of oligonucleotide
primers for detection of DNA specific for Aspergillus
species in serum samples. Briefly, DNA was extracted from the serum
samples by treatment with proteinase K and was used as a template.
Oligonucleotide primers used in the single PCR step were Asp. 5 (5'-GATAACGAACGAGACCTCGG-3') and Asp. 8 (5'-TGCCAACTCCCCTGAGCCAG-3'). Thirty cycles were performed, including 1 min of DNA denaturation at 94°C, 1 min of primer
annealing at 50°C, and 3 min of DNA extension at 72°C. Nested PCR
was performed with primers Asp. 1 (5'-CGGCCCTTAAATAGCCCGGTC-3')
and Asp. 7 (5'-CCTGAGCCAGTCCGAAGGCC-3') in a manner
similar to that described above except that primer annealing was
performed at 65°C. To avoid possible contamination of the PCR
mixtures, all reactions were performed under stringent conditions, as
recommended by Kwok and Higuchi (12). Furthermore, the room
where the PCR was performed was separate from the room where DNA
extraction was performed. Three negative controls, including reagent
controls and sera from healthy volunteers, were run along with every
five test samples for all reactions. As a positive control, the
Aspergillus fumigatus gene was also run along with the test
samples. The nested PCR products were electrophoresed on a 2% agarose
gel containing ethidium bromide, and the results were photographed.
Detection of galactomannan antigen.
Serum galactomannan
antigen was detected with a Pastorex Aspergillus kit (Sanofi
Diagnostics Pasteur, Marnes-la-Coquette, France) by the protocol
recommended by the manufacturer (5, 7, 18, 21).
 |
RESULTS |
Classification of aspergillosis.
As shown in Table
1, of the 30 patients investigated, 9 were diagnosed with pulmonary aspergilloma, 6 were diagnosed with CNPA,
3 were diagnosed with Aspergillus empyema, and 12 were
diagnosed with IPA (4 with proven IPA and 8 with presumptive IPA).
Culture of BAL fluid showed Aspergillus species in five
patients with pulmonary aspergilloma and in all patients with CNPA.
Culture of pleural effusion fluid showed growth of
Aspergillus species in all patients with
Aspergillus empyema. In contrast, because BAL could not be
performed on patients with severe underlying diseases,
Aspergillus organisms were detected in clinical specimens from only four patients with IPA.
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Results of galactomannan antigen assay and nested PCR
with sera of patients with various forms of pulmonary aspergillosis
|
|
Data from five of six patients with CNPA were analyzed in detail. The
clinical features and PCR results for these patients
are shown in Table
2. Among four PCR-positive patients,
patient
10 was treated with a low dose of corticosteroids for
idiopathic
interstitial pneumonia while patient 12 had diabetes
mellitus.
These patients were considered to have a slight systemic
immune
deficiency. For patients 11 and 12, there were relatively
extensive
pathological changes in both lungs. In contrast, for patient
13,
who had no preexisting immunosuppressive disease, the PCR was
negative and the pathological changes were restricted to the lower
lobe
of the right lung.
Comparison of results of nested PCR and galactomannan antigen
assay.
The results of nested PCR and the galactomannan antigen
assay are shown in Table 1. Twenty-two samples from 9 patients with aspergilloma, 25 samples from 6 patients with CNPA, 86 samples from 12 patients with IPA, and 8 samples from 3 patients with empyema were
tested. Among the pulmonary aspergilloma patients, one of nine (11%)
was positive by nested PCR but all were negative for the galactomannan
antigen. For six patients with CNPA, higher positive rates for nested
PCR (four of six; 67%) and galactomannan antigen (three of six; 50%)
were noted. Of the 12 patients with IPA, 10 (83%) and 6 (50%) were
positive by nested PCR and for galactomannan antigen, respectively.
Overall, the results of nested PCR were positive for 16 of 30 patients
(53%) with pulmonary aspergillosis, while for the same patients, the
galactomannan antigen assay was positive in 11 (37%) cases.
Serial changes in nested PCR and galactomannan antigen assay during
antifungal treatment.
Sera were obtained from six patients with
IPA at different intervals during the course of therapy and were tested
by nested PCR and the galactomannan antigen assay (Fig.
1). In cases where both tests were
positive (patients 16, 17, 18, and 25), there was no significant
difference in the time of positivity of DNA detection by PCR compared
to the Latek assay.

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 1.
Serial changes in the results of nested PCR and
galactomannan assays in patients with IPA treated with AMPH.
|
|
In cases of positive nested PCR, five of these patients showed a
positive PCR by day 7 after the chest radiographs showed
characteristic
shadows suggestive of IPA. The clinical manifestations
improved in
three cases (patients 16, 20, and 23) following treatment
with
amphotericin B (AMPH), which is associated with negative
results of
nested PCR. However, deterioration of chest radiographs
was noted for
two patients (patients 18 and 25) who ultimately
died, although the
nested PCR became negative during AMPH
treatment.
 |
DISCUSSION |
Pulmonary aspergillosis can be classified into various types
depending on the immune status of the host and the invasiveness of the
fungus (4, 17). Gefter et al. (8) described a new type, semi-invasive pulmonary aspergillosis, intermediate between the
invasive and saprophytic types. By introducing this definition, they
provided the concept of a wide spectrum of pulmonary aspergillosis. Thus, pulmonary aspergilloma is a condition characterized by
colonization of Aspergillus cells at preexisting disease
loci in the bronchi or lung. On the other hand, semi-invasive
aspergillosis or CNPA (3) is a condition in which the fungus
attacks the lungs in mildly immunocompromised states (e.g.,
sarcoidosis, tuberculosis, diabetes mellitus, etc.). Finally, IPA is a
condition in which the fungus invades healthy areas of the lung in
patients with systemic immune deficiency. Since the nested PCR used in
the present experiment detected the presence of DNA specific for
Aspergillus species in the serum, the results were positive
only when the blood vessels were invaded by the fungus. This conclusion
is based on our finding that the highest proportion of positive nested PCR tests were noted in patients with IPA while patients with pulmonary
aspergilloma had the lowest rate of positive tests (10 of 12 versus 1 of 9; P = 0.002 by Fisher's exact test). Thus, these
results suggested that the frequency of positive nested PCR depends on
the extent of invasiveness of Aspergillus cells.
Our results with a subgroup of patients with CNPA suggested that,
within the spectrum of pulmonary aspergillosis, the clinical manifestations in a proportion of these patients were similar to those
in patients with IPA. The former group of patients showed a slight
systemic immunodeficiency or extensive impairment of pulmonary immune
activity associated with invasion of Aspergillus cells into
the blood vessels.
Rafferty et al. (15) reported that the disease profile in 5 of their 23 patients with pulmonary aspergilloma shifted to IPA after
long-term follow-up. However, we did not see any shift in the disease
state from the noninvasive type to the invasive type, probably because
of the short period of follow-up in the present study. Invasion of
blood vessels by the fungus is considered to be one of the events
accompanying a shift in the disease state. Because the results of
nested PCR reflected the presence of fungal DNA in the serum, the
information derived from this technique might be important for
determination of the therapeutic modality or prognosis of the disease.
However, the results of nested PCR in the present study did not show a
clear correlation with the outcome of therapy. The nested PCR tended to
show a negative result shortly after the commencement of treatment
without correlation with the clinical responsiveness to antifungal
treatment. This was particularly striking in patients treated with high
doses (
0.5 mg/kg of body weight/day) of AMPH (Fig. 1). It is possible
that the nested PCR was inhibited by the presence of residual AMPH.
However, Deventer et al. (6) showed positive PCR results for
DNA of Candida albicans in blood samples of mice treated
with AMPH, suggesting that AMPH does not exhibit inhibitory activity on
PCR. Alternatively, treatment with AMPH may cause a marked decrease in
the number of Aspergillus cells in the blood. No
experimental data are available to explain these aspects of therapy.
Further evaluation is necessary for PCR monitoring of pulmonary
aspergillosis with animal models.
Several other techniques are available for the diagnosis of
aspergillosis. These include the latex agglutination test for the
detection of galactomannan antigen, which was also used in the present
study; a method for measuring the amount of
(1
3)-
-D-glucan (13, 14); and a sandwich
enzyme-linked immunosorbent assay (ELISA) for the detection of
galactomannan (16, 19, 20). The second method probably has
low specificity, since the level of (1
3)-
-D-glucan is
known to increase in patients with deep fungal infections other than
aspergillosis (14). Although the sensitivity and specificity
of the sandwich ELISA are excellent, it can only be performed in a
limited number of laboratories. Since these techniques provide a
quantitative assessment, the information obtained is usually useful for
evaluating the efficacy of treatment. In contrast, since the nested PCR
provides a target different from those of the other methods, it will be
helpful to combine the methodologies to improve early diagnosis and
observation of the disease profile.
In conclusion, we demonstrated in the present study the potential
usefulness of nested PCR for the diagnosis of invasive aspergillosis by
using serum samples as well as for detecting a shift in the pattern of
infection from a noninvasive type to invasive aspergillosis. However,
for a better evaluation of nested PCR in the diagnosis of pulmonary
aspergillosis, a long-term study with a larger population sample is necessary.
 |
ACKNOWLEDGMENTS |
We thank Takako Sato for performing galactomannan antigen assays
and Masumi Ikuta for preparing the manuscript. We also thank F. G. Issa (Department of Medicine, University of Sydney, Sydney, Australia)
for the careful reading and editing of the manuscript.
This work was supported in part by a grant-in-aid for scientific
research (C) (08670670) from the Ministry of Education, Science and
Culture, Japan.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: The Second
Department of Internal Medicine, Oita Medical University, Hasama-machi, Oita, 879-5593, Japan. Phone: 81 (97) 586-5804. Fax: 81 (97) 549-4245. E-mail: yamakami{at}oita-med.ac.jp.
 |
REFERENCES |
| 1.
|
Anderson, C. J.,
S. Craig, and E. J. Bandana, Jr.
1980.
Allergic bronchopulmonary aspergillosis and bilateral fungus balls terminating in disseminated aspergillosis.
J. Allergy Clin. Immunol.
65:140-144[Medline].
|
| 2.
|
Aslam, P. A.,
C. E. Eastridge, and F. A. Hughes, Jr.
1971.
Aspergillosis of the lung an eighteen-year experience.
Chest
59:28-32[Abstract/Free Full Text].
|
| 3.
|
Binder, R. E.,
L. J. Faling,
R. D. Pugatch,
C. Mahasaen, and G. L. Snider.
1982.
Chronic necrotizing pulmonary aspergillosis: a discrete clinical entity.
Medicine
61:109-124[Medline].
|
| 4.
|
Bodey, G. P., and S. Vartivarian.
1989.
Aspergillosis.
Eur. J. Clin. Microbiol. Infect. Dis.
8:413-437[Medline].
|
| 5.
|
Cutsem, J.,
L. Meulemans,
F. Van Gerven, and D. Stynen.
1990.
Detection of circulating galactomannan by Pastorex Aspergillus in experimental invasive aspergillosis.
Mycoses
33:61-69[Medline].
|
| 6.
|
Deventer, A. J. M.,
W. H. F. Goessens,
A. Belkum,
E. W. M. Etten,
H. J. A. Vliet, and H. A. Verbrugh.
1996.
PCR monitoring of response to liposomal amphotericin B treatment of systemic candidiasis in neutropenic mice.
J. Clin. Microbiol.
34:25-28[Abstract].
|
| 7.
|
Dupont, B.,
M. Huber,
S. J. Kim, and J. E. Bennett.
1987.
Galactomannan antigenemia and antigenuria in aspergillosis: study in patients and experimentally infected rabbits.
J. Infect. Dis.
155:1-11[Medline].
|
| 8.
|
Gefter, W. B.,
T. R. Weingrad,
D. M. Epstein,
R. H. Ochs, and W. T. Miller.
1981.
"Semi-invasive" pulmonary aspergillosis.
Radiology
140:313-321[Abstract/Free Full Text].
|
| 9.
|
Gefter, W. B.
1992.
The spectrum of pulmonary aspergillosis.
J. Thorac. Imaging
7:56-74[Medline].
|
| 10.
|
Greene, R.
1981.
The pulmonary aspergilloses: three distinct entities or spectrum of disease.
Radiology
140:527-530[Abstract/Free Full Text].
|
| 11.
| Hashimoto, A., Y. Yamakami, P. Kamberi, E. Yamagata, R. Karashima, H. Nagaoka, and M. Nasu. Comparison of PCR,
(1 3)- -D-glucan and galactomannan assays in sera of
rats with experimental invasive aspergillosis. J. Clin. Lab.
Anal., in press.
|
| 12.
|
Kwok, S., and R. Higuchi.
1989.
Avoiding false positives with PCR.
Nature (London)
339:237-238[Medline].
|
| 13.
|
Mitsutake, K.,
S. Kohno,
T. Miyazaki,
Y. Yamamoto,
K. Yanagihara,
H. Kakeya,
A. Hashimoto,
H. Koga, and K. Hara.
1995.
Detection of (1 3)- -D-glucan in a rat model of aspergillosis.
J. Clin. Lab. Anal.
9:119-122[Medline].
|
| 14.
|
Miyazaki, T.,
S. Kohno,
K. Mitsutake,
S. Maesaki,
K. Tanaka,
N. Ishikawa, and K. Hara.
1995.
Plasma (1 3)- -D-glucan and fungal antigenemia in patients with candidemia, aspergillosis, and cryptococcosis.
J. Clin. Microbiol.
33:3115-3118[Abstract].
|
| 15.
|
Rafferty, P.,
B. A. Biggs,
G. K. Crompton, and I. W. Grant.
1983.
What happens to patients with pulmonary aspergilloma? Analysis of 23 cases.
Thorax
38:579-583[Abstract/Free Full Text].
|
| 16.
|
Swanink, C. M. A.,
J. F. G. M. Meis,
A. J. M. M. Rijs,
J. P. Donnelly, and P. E. Verweij.
1997.
Specificity of a sandwich enzyme-linked immunosorbent assay for detecting Aspergillus galactomannan.
J. Clin. Microbiol.
35:257-260[Abstract].
|
| 17.
|
Turner-Warwick, M.
1979.
Aspergillus fumigatus and lung disease.
Postgrad. Med.
55:642-644[Abstract/Free Full Text].
|
| 18.
|
Verweij, P. E.,
A. J. M. M. Rijs,
B. E. DePauw,
A. M. Horrevorts,
J. A. A. Hoogkamp-Korstanje, and J. F. G. M. Meis.
1995.
Clinical evaluation and reproducibility of Pastorex Aspergillus antigen latex agglutination test for diagnosing invasive aspergillosis.
J. Clin. Pathol.
48:474-476[Abstract/Free Full Text].
|
| 19.
|
Verweij, P. E.,
D. Stynen,
A. J. M. M. Rijs,
B. E. de Pauw,
J. A. A. Hoogkamp-Korstanje, and J. F. G. M. Meis.
1995.
Sandwich enzyme-linked immunosorbent assay compared with Pastorex latex agglutination test for diagnosing invasive aspergillosis in immunocompromised patients.
J. Clin. Microbiol.
33:1912-1914[Abstract].
|
| 20.
|
Verweij, P. E.,
J.-P. Latgé,
A. J. M. M. Rijs,
W. J. G. Melchers,
B. E. De Pauw,
J. A. A. Hoogkamp-Korstanje, and J. F. G. M. Meis.
1995.
Comparison of antigen detection and PCR assay using bronchoalveolar lavage fluid for diagnosing invasive pulmonary aspergillosis in patients receiving treatment for hematological malignancies.
J. Clin. Microbiol.
33:3150-3153[Abstract].
|
| 21.
|
Warnock, D. W.,
A. B. M. Foot,
E. M. Johnson,
S. B. Mitchell,
J. M. Cornish, and A. Oakhill.
1991.
Aspergillus antigen latex test for diagnosis of invasive aspergillosis.
Lancet
338:1023-1024[Medline].
|
| 22.
|
Yamakami, Y.,
A. Hashimoto,
I. Tokimatsu, and M. Nasu.
1996.
PCR detection of DNA specific for Aspergillus species in serum of patients with invasive aspergillosis.
J. Clin. Microbiol.
34:2464-2468[Abstract].
|
Journal of Clinical Microbiology, December 1998, p. 3619-3623, Vol. 36, No. 12
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Bulpa, P., Dive, A., Sibille, Y.
(2007). Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J
30: 782-800
[Abstract]
[Full Text]
-
White, P. L., Archer, A. E., Barnes, R. A.
(2005). Comparison of Non-Culture-Based Methods for Detection of Systemic Fungal Infections, with an Emphasis on Invasive Candida Infections. J. Clin. Microbiol.
43: 2181-2187
[Abstract]
[Full Text]
-
Bu, R., Sathiapalan, R. K, Ibrahim, M. M, Al-Mohsen, I., Almodavar, E., Gutierrez, M. I, Bhatia, K.
(2005). Monochrome LightCycler PCR assay for detection and quantification of five common species of Candida and Aspergillus. J Med Microbiol
54: 243-248
[Abstract]
[Full Text]
-
Lass-Florl, C., Gunsilius, E., Gastl, G., Bonatti, H., Freund, M. C., Gschwendtner, A., Kropshofer, G., Dierich, M. P., Petzer, A.
(2004). Diagnosing Invasive Aspergillosis during Antifungal Therapy by PCR Analysis of Blood Samples. J. Clin. Microbiol.
42: 4154-4157
[Abstract]
[Full Text]
-
Yeo, S. F., Wong, B.
(2002). Current Status of Nonculture Methods for Diagnosis of Invasive Fungal Infections. Clin. Microbiol. Rev.
15: 465-484
[Abstract]
[Full Text]
-
Loeffler, J., Schmidt, K., Hebart, H., Schumacher, U., Einsele, H.
(2002). Automated Extraction of Genomic DNA from Medically Important Yeast Species and Filamentous Fungi by Using the MagNA Pure LC System. J. Clin. Microbiol.
40: 2240-2243
[Abstract]
[Full Text]
-
Raad, I., Hanna, H., Huaringa, A., Sumoza, D., Hachem, R., Albitar, M.
(2002). Diagnosis of Invasive Pulmonary Aspergillosis Using Polymerase Chain Reaction-Based Detection of Aspergillus in BAL*. Chest
121: 1171-1176
[Abstract]
[Full Text]
-
Bowman, J. C., Abruzzo, G. K., Anderson, J. W., Flattery, A. M., Gill, C. J., Pikounis, V. B., Schmatz, D. M., Liberator, P. A., Douglas, C. M.
(2001). Quantitative PCR Assay To Measure Aspergillus fumigatus Burden in a Murine Model of Disseminated Aspergillosis: Demonstration of Efficacy of Caspofungin Acetate. Antimicrob. Agents Chemother.
45: 3474-3481
[Abstract]
[Full Text]
-
Yamagata, E., Kamberi, P., Yamakami, Y., Hashimoto, A., Nasu, M.
(2000). Experimental Model of Progressive Disseminated Trichosporonosis in Mice with Latent Trichosporonemia. J. Clin. Microbiol.
38: 3260-3266
[Abstract]
[Full Text]
-
Henry, T., Iwen, P. C., Hinrichs, S. H.
(2000). Identification of Aspergillus Species Using Internal Transcribed Spacer Regions 1 and 2. J. Clin. Microbiol.
38: 1510-1515
[Abstract]
[Full Text]
-
Nagai, H., Yamakami, Y., Hashimoto, A., Tokimatsu, I., Nasu, M.
(1999). PCR Detection of DNA Specific for Trichosporon Species in Serum of Patients with Disseminated Trichosporonosis. J. Clin. Microbiol.
37: 694-699
[Abstract]
[Full Text]